According to a new research report “Niemann-Pick Disease Type C (NPC) Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, NPC currently exhibits a proliferating pipeline with 12 therapeutic candidates.

PC Pipeline Insights

Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances when gets collected in the brain tissues, it affects neurologic and psychiatric function.

The disease shows its first signs in mild-to-late childhood with the insidious onset of ataxia, dementia, and vertical supranuclear gaze palsy (VSGP). The occurrence of NPC can be confirmed by biochemical testing. NPC can also be diagnosed by skin test, in order to assess how the cells, move and store cholesterol. Furthermore, testing for the cells’ ability to modify cholesterol (cholesterol esterification test) has also been used for diagnostic purpose. Recently, blood-based testing for biomarkers (oxysterols, lysosphingolipids, bile acid metabolites) and molecular gene sequencing of NPC1 and NPC2 have replaced these methods.

NPC can be managed by treating symptoms including dystonia, seizures, and cataplexy. Also, preventing secondary complications, such as chest physical therapy and increased spasticity can reduce the occurrence of NPC.

Insights into Pipeline Segments

According to the research, many drugs acting as a therapeutic against NPC are administered orally. It has been found that oral route of administration is easy to use, non-invasive, and ensures high level of patient satisfaction.

Increasing Strategic Developments are Expected to Contribute to the Growth of NPC Therapeutics Pipeline

In the wake of strategic developments, various companies are investing in the development of therapeutic drugs for NPC, and also plan to expand their portfolio in near future. For instance, in February 2018, Oraxion Therapeutics Inc. entered into an agreement with a U.S. based biopharmaceutical company, amounting to $125 million. The agreement provides the biopharma partner the exclusive option to license its lead asset ORX-301, for the treatment of NPC and Focal Segmental Glomerulosclerosis (FSGS). However, the name of the biopharmaceutical partner was not revealed.

Designations Granted by Regulatory Bodies to Play a Pivotal Role in NPC Therapeutics Pipeline Development

It has been observed that regulatory bodies are granting designations to the pipeline drugs, in order to pace up the development process of these drugs. For instance, IntraBio Inc.’s IB1001 was granted Rare Pediatric Disease Designation by the USFDA in April 2018 and Orphan Drug Designation by USFDA and EMA in February 2018 and April 2017, respectively. Similarly, Orphazyme A/S’s arimoclomol has been granted Orphan Drug Designation (in January 2015), Fast-Track Designation (in June 2016), and Rare Pediatric Disease Designation (in January 2018) by the USFDA.

Some of the key players involved in the development of NPC therapeutics are Orphazyme A/S, IntraBio Inc., CTD Holdings Inc., Mallinckrodt plc, SOM INNOVATION BIOTECH SL, Neurotrope Inc., Actelion Pharmaceuticals Ltd., Okklo Life Sciences BV, Amicus Therapeutics Inc., Oraxion Therapeutics Inc., and COI Pharmaceuticals Inc.

Browse report overview with detailed TOC on "Niemann-Pick Disease Type C (NPC) Therapeutics - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations and Other Developments" at:https://www.pharmaproff.com/report/npc-therapeutics

NPC Therapeutics Pipeline Analysis

• By Phase
• By Molecule Type
• By Route of Administration
• By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of NPC. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the NPC therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to NPC. The report also provides epidemiology forecast of NPC for seven major markets, including the U.S., Japan, and EU5 countries (U.K., Germany, France, Italy, and Spain).